

1. Robilotto AT, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer Prostatic Dis. 2013; 16(1):41-9.
2. Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Mouraviev V, Polascik TJ, Gage AA, Baust JG. Use of 1,25alpha dihydroxyvitamin D₃ as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer Prostatic Dis. 2011; 14(2):97-104.
3. Baust JM, Klossner DP, Robilotto A, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JG. Vitamin D₃ cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. BJU Int. 2011; 109(6):949-58.
4. Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Vujaskovic Z, Satoh T, Baba S, Baust JM, Baust JG, Polascik TJ. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology. 2010; 61(1):148-54.
5. Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Caso J, Satoh T, Baba S, Vujaskovic Z, Baust JM, Baust JG, Polascik TJ. Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology. 2010; 76(3):764 e14-20.
6. Baust JG, Klossner DP, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JM. Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate cancer and prostatic diseases. 2010; 13(2):151-61.
7. Baust JG, Gage AA, Robilotto AT, Baust JM. The pathophysiology of thermoablation: optimizing cryoablation. *Curr Opin Urol* 2009; 19(2):127-32.
8. Babaian Chair RJ, Donnelly Facilitator B, Bahn D, Baust JG, Dineen M, Ellis D, Katz A, Pisters L, Rukstalis D, Shinohara K, Thrasher JB. Best Practice Statement on Cryosurgery for the Treatment of Localized Prostate Cancer. *J Urol* 2008; 180(5):1993-2004.
9. Klossner DP, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. *BJU Int* 2008; 101(10):1310-6.
10. Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. *Urology* 2008; 71(3):515-8.
11. Klossner DP, Robilotto AT, Clarke DM, Van Buskirk RG, Baust JM, Gage AA, Baust JG. Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems. *Cryobiology* 2007; 55(3):189-99.
12. Robilotto AT, Clarke D, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Development of a tissue engineered human prostate tumor equivalent for use in the evaluation of cryoablative techniques. *Technol Cancer Res Treat* 2007; 6(2):81-9.
13. Baust JG, Gage AA, Klossner DP, Clarke D, Miller R, Cohen J, Katz A, Polascik T, Clarke H, Baust JM. Issues critical to the successful application of cryosurgical ablation of the prostate. *Technol Cancer Res Treat* 2007; 6(2):97-109.

Prostate Cancer Cryotherapy

14. Clarke DM, Robilotto AT, Van Buskirk RG, Baust JG, Gage AA, Baust JM. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. *Prostate Cancer Prostatic Dis* 2007; 10(2):175-84.
15. Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. *Cryobiology* 2004; 49(1):45-61.
16. Baust JG, Gage AA, Clarke D, Baust JM, Van Buskirk R. Cryosurgery--a putative approach to molecular-based optimization. *Cryobiology* 2004; 48(2):190-204.
17. Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. *Cryobiology* 2001; 42(4):274-85.
18. Hollister WR, Mathew AJ, Baust JG, Van Buskirk RG. Effects of freezing on cell viability and mechanisms of cell death in a human prostate cell line. *Mol. Urol.* 1998; 2:213-8.
19. Kaplan SA, Greenberg R, Baust JG. A comparative assessment of cryosurgical devices: application to prostatic disease. *Urology* 1995; 45(4):692-9.

Selected Recent Prostate Cancer/Cryotherapy Abstracts Presented at Society for Cryobiology Annual Meetings

- Baust JM, Klossner DP, Robilotto A, Van Buskirk RG, Gage AA, Polascik TJ, Baust JG. Vitamin D3 therapy increases cryoablation efficacy: A novel strategy for the treatment of prostate cancer. *Cryobiology*. 2014; 69(1):198.
- Baust JM, Klossner DP, Van Buskirk RG, Snyder KK, Gage AA, Baust JG. Androgen receptor protein expression influences freeze sensitivity of prostate cancer cells. *Cryobiology*. 2014; 69(1):199.
- Baust JM, Snyder KK, Santucci KL, Robilotto AT, Smith J, McKain J, Sahay A, Baust JG. Assessment of SCN and argon cryoablation devices in an in vivo-like 3-D tissue engineered prostate and renal cancer model. *Cryobiology*. 2014; 69(1):198.
- Robilotto AT, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Rapid induction of apoptosis at ultra low temperatures enhances the efficacy of prostate cancer cryoablation. *Cryobiology*. 2014; 69(1):198-9.
- Baust JM, Klossner D, Gage A, Buskirk RV, Baust JG. Akt signaling mediates prostate cancer response to cryoablation. *Cryobiology*. 2013; 67(3):427-8.
- Baust JM, Klossner DP, Van Buskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JG. Targeted modulation of integrin expression increases freeze sensitivity of androgen-insensitive prostate cancer. *Cryobiology*. 2013; 66(3):354.
- Robilotto AT, Van Buskirk RG, Gage AA, Baust JM, Baust JG. Development of a tissue engineered human prostate tumor equivalent: Evaluation of cryoablative techniques. *Cryobiology*. 2013; 66(3):354-5.
- Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Mouraviev V, Polascik TJ, Baust JG. The use of 1,25[α] dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. *Cryobiology*. 2013; 66(3):352-3.
- Santucci KL, Snyder KK, Robilotto A, Baust JM, Baust JG. Vitamin D₃ cryosensitization in androgen

Prostate Cancer Cryotherapy

- insensitive prostate cancer. *Cryobiology*. 2013; 67(3):426.
- Robilotto AT, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Rapid induction of apoptosis at ultra low temperatures enhances the efficacy of prostate cancer cryoablation. *Cryobiology*. 2013; 66(3):354.
- Baust JM, Klossner DP, Van Buskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JG. Targeted modulation of integrin expression increases freeze sensitivity of androgen-insensitive prostate cancer. *Cryobiology*. 2010; 61(3):395.
- Baust JM, Snyder KK, Gage A, Van Buskirk RG, Baust JG. Investigation of neuronal cell stress response to transient freezing associated with cryosurgical ablation of the prostate. *Cryobiology*. 2010; 61(3):364.
- Robilotto AT, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Differential cell signaling in human prostate cancer cells frozen in monolayers versus a three dimensional prostate tumor model: the PI3 kinase-AKT pathway. *Cryobiology*. 2010; 61(3):364.
- Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Baust JG. Investigating the role of cell cycle in a prostate cancer cryosurgical model. *Cryobiology*. 2010; 61(3):363.
- Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Mouraviev V, Polascik TJ, Baust JG. The use of 1,25[alpha] dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. *Cryobiology*. 2010; 61(3):395.
- Baust JM, Klossner DP, Van Buskirk RG, Baust JG. Integrin expression yields increased freeze resistance in androgen-insensitive prostate cancer. *Cryobiology*. 2008; 57:327.
- Baust JG, Klossner DP, Clarke DM, Van Buskirk RG, Gage AA, Baust JM. Androgen receptor protein expression influences freeze sensitivity of prostate cancer cells. *Cryobiology*. 2007; 55:362.
- Robilotto AT, Clarke DM, Van Buskirk RG, Gage AA, Baust JG, Baust JM. Modeling cryosurgical outcome through the use of a novel, in vitro tissue engineered human prostate model. *Cryobiology*. 2006; 53:377.
- Robilotto AT, Clarke DM, Van Buskirk RG, Gage AA, Baust JG, Baust JM. Development of a tissue engineered prostate tumor equivalent: Evaluation of cryoablative techniques. *Cryobiology*. 2006; 53:439.
- Klossner DP, Clarke DM, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Thermal therapeutic options in the treatment of prostate cancer: Cellular responses to cryosurgery and hyperthermia. *Cryobiology*. 2006; 53:438.
- Klossner DP, Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Androgen receptor involvement in the freezing response of prostate cancer cell lines. *Cryobiology*. 2006; 53:376-7.
- Baust JG, Clarke D, Chatterjee S *et al*. Cryosurgical Modeling: Sequenced Cryo-Chemotherapy Increases Human Prostate Cancer Cell Death. *Cryobiology*. 2000; 41:358-9.
- Clarke DM, Van Buskirk RG, Baust JG. Timing dependency in cryo-chemo combinations therapy: Model cell systems. *Cryobiology*. 1999; 39:320.